FindTrial
Sign In

Effects of Sorafenib and Radiofrequency Ablation on Hepatacellular carcinoma

Effects of Sorafenib and Radiofrequency Ablation on Hepatacellular carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-TNRC-10001065
Enrollment
Unknown
Registered
2010-10-23
Start date
2010-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatacellular carcinoma

Interventions

group B:RFA
group A:sorafenib+RFA

Sponsors

Beijing you-an hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Male or female ,age arranged from 18 to 85; 2. According to BCLC; 3. Liver function child-pugh A or/and B; 4. PLT>50*10^9/L; 5. Volunteer signed consent

Exclusion criteria

Exclusion criteria: 1. Occurred gut biood in 3 months; 2. Serious coagulation obstruction,PLT<50*10^9/L; 3. Serious liver cirrhosis (child-pugh c); 4. Medium ascites; 5. Uncontrolled infections: septicemia,bile duct infection,liver abscess and etc. 6. Serious diseases of heart,brain and kindey ; 7. Prehnancy and breast-feed women; 8. Not suitable for the study.

Design outcomes

Primary

MeasureTime frame
abdomen CT;—

Secondary

MeasureTime frame
liver function and blood biochemistry;a-fetoprotein;—

Countries

China

Contacts

Public ContactJiasheng Zheng
zhengjiasheng6@yahoo.com+86 10 83997338

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026